vs

Side-by-side financial comparison of Churchill Downs Inc (CHDN) and INTEGRA LIFESCIENCES HOLDINGS CORP (IART). Click either name above to swap in a different company.

Churchill Downs Inc is the larger business by last-quarter revenue ($663.0M vs $434.9M, roughly 1.5× INTEGRA LIFESCIENCES HOLDINGS CORP). On growth, Churchill Downs Inc posted the faster year-over-year revenue change (3.1% vs -1.7%). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs -13.7%).

Churchill Downs Incorporated is the parent company of Churchill Downs. The company has evolved from one racetrack in Louisville, Kentucky, to a multi American-state-wide, publicly traded company with racetracks, casinos and an online wagering company among its portfolio of businesses.

Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.

CHDN vs IART — Head-to-Head

Bigger by revenue
CHDN
CHDN
1.5× larger
CHDN
$663.0M
$434.9M
IART
Growing faster (revenue YoY)
CHDN
CHDN
+4.9% gap
CHDN
3.1%
-1.7%
IART
Faster 2-yr revenue CAGR
IART
IART
Annualised
IART
8.6%
-13.7%
CHDN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CHDN
CHDN
IART
IART
Revenue
$663.0M
$434.9M
Net Profit
$83.0M
Gross Margin
50.8%
Operating Margin
21.6%
5.3%
Net Margin
12.5%
Revenue YoY
3.1%
-1.7%
Net Profit YoY
7.8%
EPS (diluted)
$1.16
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHDN
CHDN
IART
IART
Q1 26
$663.0M
Q4 25
$665.9M
$434.9M
Q3 25
$683.0M
$402.1M
Q2 25
$934.4M
$415.6M
Q1 25
$642.6M
$382.7M
Q4 24
$624.2M
$442.6M
Q3 24
$628.5M
$380.8M
Q2 24
$890.7M
$418.2M
Net Profit
CHDN
CHDN
IART
IART
Q1 26
$83.0M
Q4 25
$51.3M
Q3 25
$38.1M
$-5.4M
Q2 25
$216.9M
$-484.1M
Q1 25
$76.7M
$-25.3M
Q4 24
$71.7M
Q3 24
$65.4M
$-10.7M
Q2 24
$209.3M
$-12.4M
Gross Margin
CHDN
CHDN
IART
IART
Q1 26
Q4 25
50.8%
Q3 25
51.5%
Q2 25
50.4%
Q1 25
50.8%
Q4 24
56.3%
Q3 24
52.6%
Q2 24
54.0%
Operating Margin
CHDN
CHDN
IART
IART
Q1 26
21.6%
Q4 25
18.5%
5.3%
Q3 25
14.3%
2.9%
Q2 25
35.1%
-123.4%
Q1 25
20.9%
-4.0%
Q4 24
20.3%
8.0%
Q3 24
20.0%
-2.1%
Q2 24
37.0%
-0.7%
Net Margin
CHDN
CHDN
IART
IART
Q1 26
12.5%
Q4 25
7.7%
Q3 25
5.6%
-1.3%
Q2 25
23.2%
-116.5%
Q1 25
11.9%
-6.6%
Q4 24
11.5%
Q3 24
10.4%
-2.8%
Q2 24
23.5%
-3.0%
EPS (diluted)
CHDN
CHDN
IART
IART
Q1 26
$1.16
Q4 25
$-0.03
Q3 25
$-0.07
Q2 25
$-6.31
Q1 25
$-0.33
Q4 24
$0.25
Q3 24
$-0.14
Q2 24
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHDN
CHDN
IART
IART
Cash + ST InvestmentsLiquidity on hand
$200.0M
$263.7M
Total DebtLower is stronger
$840.0M
$726.6M
Stockholders' EquityBook value
$1.0B
Total Assets
$7.5B
$3.6B
Debt / EquityLower = less leverage
0.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHDN
CHDN
IART
IART
Q1 26
$200.0M
Q4 25
$200.6M
$263.7M
Q3 25
$180.5M
$267.9M
Q2 25
$182.4M
$253.6M
Q1 25
$174.2M
$273.3M
Q4 24
$175.5M
$273.6M
Q3 24
$152.7M
$277.6M
Q2 24
$140.3M
$296.9M
Total Debt
CHDN
CHDN
IART
IART
Q1 26
$840.0M
Q4 25
$726.6M
Q3 25
$736.3M
Q2 25
$745.9M
Q1 25
$755.6M
Q4 24
$760.5M
Q3 24
$765.3M
Q2 24
$770.2M
Stockholders' Equity
CHDN
CHDN
IART
IART
Q1 26
Q4 25
$1.0B
$1.0B
Q3 25
$1.0B
$1.0B
Q2 25
$1.0B
$1.0B
Q1 25
$1.1B
$1.5B
Q4 24
$1.1B
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.0B
$1.5B
Total Assets
CHDN
CHDN
IART
IART
Q1 26
$7.5B
Q4 25
$7.5B
$3.6B
Q3 25
$7.5B
$3.6B
Q2 25
$7.4B
$3.7B
Q1 25
$7.3B
$4.1B
Q4 24
$7.3B
$4.0B
Q3 24
$7.2B
$4.1B
Q2 24
$7.2B
$4.1B
Debt / Equity
CHDN
CHDN
IART
IART
Q1 26
Q4 25
0.70×
Q3 25
0.71×
Q2 25
0.72×
Q1 25
0.50×
Q4 24
0.49×
Q3 24
0.50×
Q2 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHDN
CHDN
IART
IART
Operating Cash FlowLast quarter
$295.0M
$11.8M
Free Cash FlowOCF − Capex
$-5.4M
FCF MarginFCF / Revenue
-1.2%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
3.55×
TTM Free Cash FlowTrailing 4 quarters
$-31.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHDN
CHDN
IART
IART
Q1 26
$295.0M
Q4 25
$11.8M
Q3 25
$187.7M
$40.9M
Q2 25
$8.9M
Q1 25
$246.5M
$-11.3M
Q4 24
$50.7M
Q3 24
$169.4M
$22.5M
Q2 24
$40.4M
Free Cash Flow
CHDN
CHDN
IART
IART
Q1 26
Q4 25
$-5.4M
Q3 25
$166.3M
$25.8M
Q2 25
$-11.2M
Q1 25
$233.9M
$-40.2M
Q4 24
$21.1M
Q3 24
$154.4M
$-7.2M
Q2 24
$10.7M
FCF Margin
CHDN
CHDN
IART
IART
Q1 26
Q4 25
-1.2%
Q3 25
24.3%
6.4%
Q2 25
-2.7%
Q1 25
36.4%
-10.5%
Q4 24
4.8%
Q3 24
24.6%
-1.9%
Q2 24
2.6%
Capex Intensity
CHDN
CHDN
IART
IART
Q1 26
Q4 25
2.6%
4.0%
Q3 25
3.1%
3.8%
Q2 25
2.0%
4.8%
Q1 25
2.0%
7.6%
Q4 24
5.4%
6.7%
Q3 24
2.4%
7.8%
Q2 24
2.5%
7.1%
Cash Conversion
CHDN
CHDN
IART
IART
Q1 26
3.55×
Q4 25
Q3 25
4.93×
Q2 25
Q1 25
3.21×
Q4 24
Q3 24
2.59×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHDN
CHDN

Live and Historical Racing$297.0M45%
Gaming$257.0M39%
Wagering Services and Solutions$109.0M16%

IART
IART

Neurosurgery$226.2M52%
Asia Pacific$53.7M12%
Instruments$52.3M12%
ENT$44.8M10%
Other$38.9M9%
Rest Of The World$19.0M4%

Related Comparisons